Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 26.10.2021 at 12:00 PM CEST
Settings

Settings

Goto Application

1. WO2021040570 - MEDICAMENT AND METHOD FOR TREATING INFECTIOUS DISEASES

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

Claims

1. A medicament, which presents a technology-processed product resulting from multiple serial dilutions of the stock substances of antibodies to the bΐ domain of the major histocompatibility complex class II molecule (HLA-DRB1) and to p2-microglobulin (b2-MO).

2. The medicament of claim 1 for the treatment of bacterial infections.

3. The medicament of claim 2, wherein the bacterial infection is a urinary tract infection.

4. The medicament of claim 3, wherein the urinary tract infection is cystitis.

5. The medicament of claim 3, wherein the urinary tract infection is prostatitis.

6. The medicament of claim 2, wherein the bacterial infection is a gastrointestinal infection.

7. The medicament of claim 6, wherein the bacterial gastrointestinal infection is a bacterial intestinal infection.

8. The medicament of claim 2, wherein the bacterial infection is a bacterial skin infection.

9. The medicament of claim 2, wherein the bacterial infection is a respiratory tract infection.

10. The medicament of claim 9, wherein the bacterial respiratory tract infection is tuberculosis.

11. The medicament of claim 2, wherein the bacterial infection is salmonellosis.

12. The medicament of claim 2, wherein the bacterial infection is an E.coli infection.

13. The medicament of claim 2, wherein the bacterial infection is a streptococcal infection.

14. The medicament of claim 2, wherein the bacterial infection is an infection caused by Klebsiella pneumoniae.

15. The medicament of claim 2, wherein the bacterial infection is caused by bacteria resistant to one or more known antibiotics.

16. The medicament of claim 1, wherein the technology-processed product resulting from multiple serial dilutions of the stock substance of antibodies to HLA-DRB1 is an aqueous or aqueous-alcoholic solution obtained from serial dilutions of the matrix solution of antibodies to HLA-DRB1, with repeated shaking of each dilution.

17. The medicament of claim 16, wherein the matrix solution of antibodies is used at a concentration of 0.5 ÷ 5.0 mg/ml.

18. The medicament of claim 1, wherein the antibody is a monoclonal, polyclonal or natural antibody to HLA-DRB1.

19. The medicament of claim 1, wherein the technology-processed product resulting from multiple serial dilutions of the stock substance of antibodies to b2-microglobulin is an aqueous or aqueous-alcoholic solution obtained from serial dilutions of the matrix solution of antibodies to p2-microglobulin, with repeated shaking of each dilution.

20. The medicament of claim 19, wherein the matrix solution of antibodies is used at a concentration of 0.5 ÷ 5.0 mg/ml.

21. The medicament of claim 1, wherein the antibody is a monoclonal, polyclonal or natural antibody to p2-microglobulin.

22. The medicament of claim 1, which further comprises pharmaceutically acceptable supplements.

23. The medicament of claim 1 formulated as a solid dosage form, which contains effective amounts of neutral carrier granules impregnated with a technology-processed product resulting from multiple serial dilutions of the stock substances of antibodies to HLA DRB1 and antibodies to p2-microglobulin as well as pharmaceutically acceptable excipients.

24. A combination of an antibiotic and the medicament of claim 1 for either simultaneous or successive administration to treat bacterial infections.

25. The combination of claim 24, wherein the bacterial infection is caused by bacteria resistant to one or more known antibiotics.

26. The combination of claim 24, wherein the bacterial infection is a urinary tract infection.

27. The combination of claim 26, wherein the urinary tract infection is cystitis.

28. The combination of claim 26, wherein the urinary tract infection is prostatitis.

29. The combination of claim 24, wherein the bacterial infection is a gastrointestinal infection.

30. The combination of claim 29, wherein the bacterial gastrointestinal infection is a bacterial intestinal infection.

31. The combination of claim 24, wherein the bacterial infection is a bacterial skin infection.

32. The combination of claim 24, wherein the bacterial infection is a respiratory tract infection.

33. The combination of claim 32, wherein the bacterial respiratory tract infection is tuberculosis.

34. The combination of claim 24, wherein the bacterial infection is salmonellosis.

35. The combination of claim 24, wherein the bacterial infection is an E.coli infection.

36. The combination of claim 24, wherein the bacterial infection is a streptococcal infection.

37. The combination of claim 24, wherein the bacterial infection is an infection caused by Klebsiella pneumoniae.

38. The combination of claim 24, wherein the antibiotic is selected from the class of penicillins.

39. The combination of claim 24, wherein the antibiotic is selected from the class of aminoglycosides.

40. The combination of claim 24, wherein the antibiotic is selected from the class of macrolides.

41. The combination of claim 24, wherein the antibiotic is selected from the class of oxazolidinones.

42. A method of treating bacterial infection, which comprises administering the medicament of claim 1.

43. The method of claim 42, wherein the bacterial infection is a urinary tract infection.

44. The method of claim 43, wherein the urinary tract infection is cystitis.

45. The method of claim 43, wherein the urinary tract infection is prostatitis.

46. The method of claim 42, wherein the bacterial infection is a gastrointestinal infection.

47. The method of claim 46, wherein the bacterial gastrointestinal infection is a bacterial intestinal infection.

48. The method of claim 42, wherein the bacterial infection is a bacterial skin infection.

49. The method of claim 42, wherein the bacterial infection is a respiratory tract infection.

50. The method of claim 49, wherein the bacterial respiratory tract infection is tuberculosis.

51. The method of claim 42, wherein the bacterial infection is salmonellosis.

52. The method of claim 42, wherein the bacterial infection is an E.coli infection.

53. The method of claim 42, wherein the bacterial infection is a streptococcal infection.

54. The method of claim 42, wherein the bacterial infection is an infection caused by Klebsiella pneumoniae.

55. The method of claim 42, which further comprises administration of an antibiotic.

56. The method of claim 42, wherein the bacterial infection is caused by bacteria resistant to one or more known antibiotics.

57. The method of claim 55, wherein the antibiotic is administered at the known effective dose.

58. The method of claim 55, wherein the antibiotic is co-administered either simultaneously or successively with the medicament of claim 1.

59. The method of claim 55, wherein the antibiotic is selected from the class of penicillins.

60. The method of claim 55, wherein the antibiotic is selected from the class of aminoglycosides.

61. The method of claim 55, wherein the antibiotic is selected from the class of macrolides.

62. The method of claim 55, wherein the antibiotic is selected from the class of oxazolidinones.

63. A method of reducing bacterial resistance to antibiotic therapy, which comprises co-administration of an antibiotic and the medicament of claim 1.

64. The method of claim 63, wherein the medicament of claim 1 is co administered either simultaneously or successively with an antibiotic.

65. The method of claim 63, wherein the antibiotic is administered at the known effective dose.

66. The method of claim 63 , wherein the antibiotic is selected from the class of penicillins.

67. The method of claim 63 , wherein the antibiotic is selected from the class of aminoglycosides.

68. The method of claim 63, wherein the antibiotic is selected from the class of macrolides.

69. The method of claim 63 , wherein the antibiotic is selected from the class of oxazolidinones.

70. A method of enhancing antibiotic efficacy, which further comprises administering the medicament of claim 1.

71. The method of claim 98, wherein the medicament of claim 1 is co administered either simultaneously or successively with an antibiotic.

72. The method of claim 70, wherein the antibiotic is selected from the class of penicillins.

73. The method of claim 70, wherein the antibiotic is selected from the class of aminoglycosides.

74. The method of claim 70, wherein the antibiotic is selected from the class of macrolides.

75. The method of claim 70, wherein the antibiotic is selected from the class of oxazolidinones.

76. The method of claim 70, wherein the antibiotic is administered at 50% of the effective dose (ED50).

77. A medicament, which presents a technology-processed product resulting from multiple serial dilutions of the stock substances of a) antibodies to the bΐ domain of the major histocompatibility complex class II molecule (HLA-DRB1), b) antibodies to p2-microglobulin (b2-MO), c) antibodies to interferon gamma (IFN-g) and d) antibodies to CD4.

78. The medicament of claim 77 for the treatment of infectious diseases.

79. The medicament of claim 78, wherein the infectious disease is a viral infection.

80. The medicament of claim 79, wherein the viral infection is URL 81. The medicament of claim 79, wherein the viral infection is influenza.

82. The medicament of claim 78, wherein the infectious disease is a bacterial infection.

83. The medicament of claim 78, wherein the infectious disease is a mixed infection.

84. The medicament of claim 78, wherein the infectious disease is a secondary infection.

85. The medicament of claim 84, wherein the secondary infection is viral/bacterial pneumonia.

86. The medicament of claim 77, wherein the technology-processed product resulting from multiple serial dilutions of the stock substance of antibodies to HLA-DRB1 is an aqueous or aqueous-alcoholic solution obtained from serial dilutions of the matrix solution of antibodies to HLA-DRB1, with repeated shaking of each dilution.

87. The medicament of claim 77, wherein the technology-processed product resulting from multiple serial dilutions of the stock substance of antibodies to p2-microglobulin is an aqueous or aqueous-alcoholic solution obtained from serial dilutions of the matrix solution of antibodies to p2-microglobulin, with repeated shaking of each dilution.

88. The medicament of claim 77, wherein the technology-processed product resulting from multiple serial dilutions of the stock substance of antibodies to interferon gamma is an aqueous or aqueous-alcoholic solution obtained from serial dilutions of the matrix solution of antibodies to interferon gamma, with repeated shaking of each dilution.

89. The medicament of claim 77, wherein the technology-processed product resulting from multiple serial dilutions of the stock substance of antibodies to CD4 is an aqueous or aqueous-alcoholic solution obtained from serial dilutions of the matrix solution of antibodies to CD4, with repeated shaking of each dilution.

90. The medicament of claims 86, 87, 88, and 89, wherein the matrix solution of antibodies is used at a concentration of 0.5 ÷ 5.0 mg/ml.

91. The medicament of claim 86, wherein the antibody is a monoclonal, polyclonal or natural antibody to HLA-DRB1.

92. The medicament of claim 87, wherein the antibody is a monoclonal, polyclonal or natural antibody to p2-microglobulin.

93. The medicament of claim 88, wherein the antibody is a monoclonal, polyclonal or natural antibody to interferon gamma.

94. The medicament of claim 89, wherein the antibody is a monoclonal, polyclonal or natural antibody to CD4.

95. The medicament of claim 77, which further comprises pharmaceutically acceptable supplements.

96. The medicament of claim 77 formulated as a solid dosage form, which contains effective amounts of neutral carrier granules impregnated with a technology-processed product resulting from multiple serial dilutions of the stock substances of antibodies to HLA DRB1, antibodies to b2-MO, antibodies to IFN-g and antibodies to CD4 as well as pharmaceutically acceptable excipients.

97. A method for the treatment of infectious diseases, which comprises administering the medicament of claim 77.

98. The method of claim 97, wherein the infectious disease is a viral infection.

99. The method of claim 98, wherein the viral infection is URI.

100. The method of claim 99, wherein the viral infection is influenza.

101. The method of claim 98, wherein the infectious disease is a bacterial infection.

102. The method of claim 98, wherein the infectious disease is a mixed infection.

103. The method of claim 98, wherein the infectious disease is a secondary infection.

104. The method of claim 103, wherein the secondary infection is viral/bacterial pneumonia.